" class="no-js "lang="en-US"> Alison Burklund - Medtech Alert
Friday, September 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Alison Burklund

Alison Burklund

About Alison Burklund

Alison is pioneering novel technological approaches to disease diagnosis and molecular testing. She is passionate about improving health through innovation, entrepreneurship, and impact-driven technology development.

Related Story

Fundraising

 Nanopath Secures $10 Million in Series A Funding to Develop and Commercialize Point-of-Care Diagnostics for Women's Health | Pharmtech Focus

Nanopath Secures $10 Million in Series A Funding to Develop and Commercialize Point-of-Care Diagnostics for Women's Health

August 10 2022

Nanopath Inc., a molecular diagnostics company enabling high-quality molecular testing in minutes, announced today that […]